Comparison of HPV DNA Vaccines Employing Intracellular Targeting Strategies

Human papillomavirus (HPV) E6 and E7 are consistently expressed and are responsible for the malignant transformation of HPV-associated lesions. Thus, E6 and E7 represent ideal targets for therapeutic HPV vaccine development. Scientists at JHU previously used a gene gun approach to test several intracellular targeting strategies that are able to route model antigen, HPV-16 E7 to desired subcellular compartments and enhance antigen processing and presentation to T-cells in a context of DNA vaccines. Vaccination of DNA vaccines encoding E7 antigen linked to pcDNA3-CRT/E7 generated the highest number of E7-specific CD8+ T cells and the most potent long-term protection and treatment effects against E7-expressing tumors in mice. It appears that DNA vaccine encoding CRT/E7 may be a suitable candidate for human trials for the control of HPV infections and HPV-associated lesions. Description (Set) Proposed Use (Set) This invention presents a novel strategy for enhancing DNA vaccine potency.

Inventor(s): Wu, T.C.

Type of Offer: Licensing



« More Pharmaceutical Patents
« More Medical Patents

---